Curcumin

Turmeric root / powderCurcumin Phytosome (Meriva) NSF
- Form
- Curcumin bound to phosphatidylcholine (phytosome), capsules; 1 g curcumin phytosome per two capsules
- Additives
- Hypromellose capsule, leucine, calcium laurate, silicon dioxide, microcrystalline cellulose, flow agents and fillers, none on this guide's avoid list; disclosed because that's the rule
- Why this one
- A bioavailability-engineered curcumin with a large human safety record, NSF-certified, and the one I take myself. See the form note below for how it relates to the trial forms.
- SKU
- THO-SF814N
A second option: Theracurmin
The colloidal-dispersion form used in the Crohn's trial (Sugimoto 2020) is sold as Theracurmin, and it is a legitimate alternative: the trial was run on it. My caveats are its additive profile (magnesium stearate in two of the three licensed versions, plus the gum-and-dextrin carrier) and my impression that it costs more per day. Both work well for me; I would pick the phytosome. On Fullscript: Integrative Therapeutics Theracurmin HP, 60 caps, 600 mg per two, NSF, ITI-10630 (lists maltodextrin; see Section K): go.supplementsforibd.com/theracurmin
What it is
Curcumin is the yellow pigment of turmeric root and the most-studied plant compound in inflammatory bowel disease. It has randomized trials in ulcerative colitis, a positive randomized trial in Crohn's disease, and a well-understood problem: on its own, almost none of it gets absorbed. The story of curcumin in IBD is therefore really two stories, what the molecule does once it reaches inflamed tissue, and how you get it there; every engineered curcumin exists to solve the second problem.
How it works
Curcumin sits upstream of much of the inflammatory cascade. It inhibits activation of NF-κB, the transcription factor that switches on TNF-α, IL-1β, IL-6, COX-2 and iNOS, the same signaling that anti-TNF biologics interrupt further downstream. It activates the Nrf2 antioxidant response, and in colitis models it preserves tight-junction proteins and shifts the microbiome toward a less inflammatory composition. In the trials, the measurable effects were fewer relapses in patients already in remission, more patients reaching remission when added to mesalamine, and lower endoscopic activity.
The absorption problem is chemical: curcumin is nearly insoluble in water and is rapidly conjugated in the gut wall and liver, so dietary turmeric, even in generous amounts, produces blood levels close to zero. Every positive trial used either a high dose of plain curcumin (2–3 grams) or a bioavailability-enhanced form at a much lower dose.
- Category
- Polyphenol (curcuminoid), herb-derived
- Phenotype
- Ulcerative colitis (most data); Crohn's disease (one positive RCT)
- Other IBD
- Indeterminate colitis: read the UC and Crohn's evidence as yours. Microscopic colitis: no trials; plausible on mechanism (NF-κB, TNF-α), untested.
- Whole-food source
- Turmeric root, but dietary curcumin is very poorly absorbed; food and supplement are not interchangeable here
- Cross-references
- C-02 boswellia (the other phytosome) · C-14 rutin and A-02 quercetin (fellow polyphenols)
The evidence
Ulcerative colitis in remission, all patients on sulfasalazine or mesalamine. Curcumin 1 g twice daily (2 g/day) or placebo for 6 months. Significantly fewer relapses in the curcumin group (2 of 43, 4.65%, versus 8 of 39, 20.51%), with improvement in clinical and endoscopic indices. Rated low risk of bias by the Cochrane review that included it.
Mild-to-moderate UC not responding to optimized mesalamine. Curcumin 3 g/day or placebo added for 4 weeks. Clinical remission in 54% of the curcumin group vs 0% on placebo; clinical response 65% vs 13%.
Active mild-to-moderate Crohn's disease, five Japanese centers. Theracurmin 360 mg/day (a colloidal-dispersion curcumin) or placebo for 12 weeks. Clinical remission 40% vs 0% at week 12; significant reduction in endoscopic severity; healing of anal lesions at week 8. No serious adverse events. The only RCT in Crohn's, and it used an engineered form.
Curcumin added to standard therapy roughly doubled the likelihood of clinical remission (risk ratio 2.33) and improved clinical and endoscopic response; endoscopic remission did not reach significance. Heterogeneity between trials was high, different doses, forms and durations.
Mild-to-moderate UC on mesalamine; 150 mg of plain curcumin three times a day (450 mg/day) or placebo for 8 weeks. No difference in remission (31% vs 27%), response or mucosal healing. Included because it is the clearest evidence that dose and form are not details; they are the whole question.
Dose as studied
Scroll sideways to see every column →
| Study | Form | Dose | Duration |
|---|---|---|---|
| Hanai 2006 | Plain curcumin | 2 g/day (1 g twice daily) | 6 months |
| Lang 2015 | Plain curcumin | 3 g/day | 4 weeks |
| Sugimoto 2020 | Theracurmin | 360 mg/day | 12 weeks |
| Kedia 2017 | Plain curcumin | 450 mg/day (negative) | 8 weeks |
Reported as used in the trials named. Not a recommendation.
What to expect
In the induction trials, differences appeared by 4 weeks (Lang) and grew through 12 (Sugimoto); the maintenance benefit in Hanai was measured over 6 months. Stools may turn yellow-orange; mild nausea or loose stool is the common complaint at gram doses. Nothing in the trials suggested curcumin works fast enough to be a flare rescue.
Form, timing and bioavailability
Plain curcumin is roughly 1% absorbed, so the form is the whole question. Three engineered forms have human data: phytosome (curcumin bound to phosphatidylcholine, Meriva, the form matched above), colloidal dispersion (Theracurmin, the form in the Crohn's trial), and various nano- and micellar preparations. The phytosome has the largest human safety record across conditions, and in one pharmacokinetic study delivered roughly 29 times more curcuminoids than an equivalent unformulated dose. The Crohn's RCT used a different engineered form, so the product above rides on comparable-delivery logic, not on that trial. Take it with food, and read the label: phytosome products list total complex weight and curcumin content separately.
Who should be careful
People with gallstones or bile-duct obstruction (curcumin stimulates bile flow); anyone on anticoagulants or antiplatelet drugs; pregnancy at supplemental doses. Relevant to IBD: curcumin chelates iron and may reduce iron absorption, worth knowing if you are iron-deficient, as many people with IBD are.
Interactions with IBD medications
Used alongside mesalamine and sulfasalazine in every UC trial without a problem. Inhibits CYP3A4 and P-glycoprotein in laboratory studies, so it could theoretically raise blood levels of tacrolimus and cyclosporine; tell your team if you take either. No known interaction with thiopurines, methotrexate, steroids or biologics. Additive bleeding risk with anticoagulants.
Andrew's notes
Curcumin is the supplement I am most comfortable recommending in IBD, and the one with the deepest trial record in both diseases. It has been used in Ayurvedic medicine for thousands of years, and the modern trials have largely confirmed what that tradition observed: well tolerated and helpful for a meaningful share of people, and many gastroenterologists agree. The caveats are modest but real: the form decides whether the dose does anything, and it can chelate iron and add to the effect of blood thinners.



